Quan Jiang Selected Research

Thrombolytic Therapy

4/2015	Focal embolic cerebral ischemia in the rat.
4/2014	Combination treatment with N-acetyl-seryl-aspartyl-lysyl-proline and tissue plasminogen activator provides potent neuroprotection in rats after stroke.
10/2006	Detection of BBB disruption and hemorrhage by Gd-DTPA enhanced MRI after embolic stroke in rat.
7/2006	MRI of combination treatment of embolic stroke in rat with rtPA and atorvastatin.
11/2005	Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat.
1/2005	Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Quan Jiang Research Topics

Disease

26	Stroke (Strokes) 11/2023 - 08/2002
22	Neoplasms (Cancer) 12/2023 - 09/2004
18	Embolic Stroke 01/2021 - 05/2002
17	Rheumatoid Arthritis 05/2023 - 12/2009
10	Inflammation (Inflammations) 02/2024 - 11/2005
10	Ischemia 01/2018 - 08/2002
7	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2019 - 04/2011
6	Stomach Neoplasms (Stomach Cancer) 09/2023 - 01/2021
4	Pain (Aches) 09/2021 - 10/2013
4	Type 2 Diabetes Mellitus (MODY) 08/2017 - 09/2014
4	Ankylosing Spondylitis 01/2017 - 10/2013
4	Breast Neoplasms (Breast Cancer) 06/2013 - 08/2010
4	Atrophy 11/2012 - 11/2010
3	Reperfusion Injury 01/2023 - 01/2022
3	Thyroid Nodule (Nodule, Thyroid) 08/2022 - 10/2021
3	Fibromyalgia (Fibrositis) 09/2021 - 11/2019
3	Ischemic Stroke 01/2021 - 08/2004
3	Thrombosis (Thrombus) 01/2021 - 11/2005
3	Brain Injuries (Brain Injury) 01/2021 - 06/2015
3	Carcinogenesis 01/2021 - 08/2010
3	Arthritis (Polyarthritis) 01/2019 - 12/2009
3	Infarction (Infarctions) 04/2014 - 02/2002
3	Brain Ischemia (Cerebral Ischemia) 04/2014 - 08/2004
2	Infections 12/2023 - 12/2019
2	Cognitive Dysfunction 01/2023 - 07/2019
2	Microsatellite Instability 08/2022 - 08/2021
2	Rheumatic Diseases (Rheumatism) 01/2022 - 01/2020
2	Hemorrhage 01/2022 - 10/2006
2	Neoplasm Metastasis (Metastasis) 01/2021 - 02/2013
2	Body Weight (Weight, Body) 01/2020 - 03/2009
2	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 12/2019 - 04/2017
2	Carotid Artery Diseases 08/2017 - 09/2014
2	Glioma (Gliomas) 01/2012 - 03/2006
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 03/2009 - 11/2005
1	Pancreatic Neoplasms (Pancreatic Cancer) 12/2023

Drug/Important Bio-Agent (IBA)

9	Proteins (Proteins, Gene)FDA Link 02/2024 - 03/2015
7	Tissue Plasminogen Activator (Alteplase)FDA Link 04/2015 - 08/2002
6	Contrast MediaIBA 04/2017 - 09/2004
5	Therapeutic UsesIBA 09/2021 - 11/2012
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2015
5	Gadolinium DTPA (Magnevist)FDA Link 04/2017 - 08/2002
4	MicroRNAs (MicroRNA)IBA 01/2021 - 05/2015
4	qingre huoxueIBA 01/2021 - 12/2011
4	GlycosidesIBA 10/2020 - 01/2018
4	TabletsIBA 10/2020 - 01/2018
4	Sildenafil Citrate (Viagra)FDA Link 12/2011 - 02/2007
3	2-(4-toluidino)-6-naphthalenesulfonic acid (TNS)IBA 08/2022 - 10/2021
3	Neuroprotective AgentsIBA 01/2022 - 11/2005
3	Indicators and Reagents (Reagents)IBA 01/2021 - 01/2016
3	LipidsIBA 01/2020 - 11/2009
3	FibrinIBA 04/2015 - 01/2005
3	von Willebrand FactorIBA 12/2008 - 02/2002
2	Interleukin-17 (Interleukin 17)IBA 01/2024 - 01/2021
2	Capsules (Microcapsules)IBA 12/2023 - 09/2021
2	RNA (Ribonucleic Acid)IBA 09/2023 - 08/2021
2	CytokinesIBA 01/2023 - 01/2021
2	Complement System Proteins (Complement)IBA 01/2023 - 01/2022
2	InflammasomesIBA 01/2023 - 01/2023
2	Messenger RNA (mRNA)IBA 12/2022 - 10/2019
2	Amyloid (Amyloid Fibrils)IBA 01/2022 - 07/2019
2	AlbuminsIBA 01/2022 - 03/2006
2	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 01/2021
2	Immunoglobulin G (IgG)IBA 01/2022 - 01/2022
2	Peptides (Polypeptides)IBA 01/2022 - 04/2014
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2022 - 01/2021
2	Long Noncoding RNAIBA 09/2021 - 08/2021
2	oxidized low density lipoproteinIBA 01/2021 - 09/2014
2	AutoantibodiesIBA 01/2021 - 05/2019
2	bushen qiangjiIBA 11/2016 - 10/2013
2	C-Reactive ProteinIBA 01/2016 - 10/2013
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 06/2015 - 11/2005
2	GadoliniumIBA 02/2015 - 05/2002
2	daidzeinIBA 08/2014 - 08/2010
2	Estrogens (Estrogen)FDA Link 02/2014 - 08/2010
2	Tamoxifen FDA LinkGeneric 06/2013 - 04/2012
2	Estrogen ReceptorsIBA 06/2013 - 04/2012
2	IronIBA 01/2012 - 01/2012
2	Erythropoietin FDA Link 11/2010 - 03/2009
2	ferumoxides (Feridex)FDA Link 09/2007 - 08/2007
2	Protamines (Protamine Sulfate)FDA Link 09/2007 - 08/2007
2	Protons (Proton)IBA 10/2006 - 05/2005
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 07/2006 - 11/2005
2	Atorvastatin (Lipitor)FDA Link 07/2006 - 11/2005
1	Waste Products (Waste Product)IBA 02/2024
1	Anti-Bacterial Agents (Antibiotics)IBA 12/2023
1	Carbapenems (Carbapenem Antibiotics)IBA 12/2023
1	MyokinesIBA 11/2023
1	Ion Channels (Ion Channel)IBA 11/2023
1	Excitatory Amino AcidsIBA 11/2023

Therapy/Procedure

22	Therapeutics 09/2023 - 02/2003
7	Transplantation 01/2019 - 02/2003
6	Chinese Traditional Medicine (Traditional Chinese Medicine) 02/2022 - 07/2016
6	Thrombolytic Therapy 04/2015 - 01/2005
4	Drug Therapy (Chemotherapy) 01/2023 - 08/2018
3	Immunotherapy 09/2023 - 01/2021
3	Aftercare (After-Treatment) 01/2016 - 11/2005
3	Lasers (Laser) 09/2015 - 11/2005
3	Cell- and Tissue-Based Therapy (Cell Therapy) 04/2011 - 02/2003
2	Neoadjuvant Therapy 08/2018 - 10/2010
1	Critical Care (Surgical Intensive Care) 12/2023